BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026

Phase 2positivePembrolizumabPlinabulinDocetaxelPositive

AI Analysis

Summary

BeyondSpring presented updated Phase 2 data at ASCO 2026 showing durable clinical benefit of pembrolizumab plus plinabulin/docetaxel in metastatic NSCLC patients who progressed on first-line immune checkpoint inhibitor therapy.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Durable clinical benefit demonstrated in pembrolizumab plus plinabulin/docetaxel combination in metastatic NSCLC after progression on first-line immune checkpoint inhibitor therapy

Importance:6/10

Sentiment:

0.70

oncologyNSCLCimmunotherapycombination therapycheckpoint inhibitorASCO 2026clinical update

Related Companies

$BYSI

Read the original article

Published by yahoo_finance on June 2, 2026 11:00 AM

Read Original